Oryzon Genomics S.A.

Oryzon Genomics S.A. - Current Ratioverified

ORYZF

Price:

$3.645

Market Cap:

$247.28M

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company dedicated to advancing epigenetics-based therapies for individuals battling cancer and central nervous system (CNS) conditions. The company's clinical pipeline features two key compounds. Iadademstat (ORY-1001), a selective LSD1 inhibitor, is currently undergoing Phase II trials for various oncological indications. Similarly, vafidemstat (ORY-2001), another LSD1 inhibitor specifically designed for CNS applications, is also in Phase II for the treatment of neurological and psychiatric illnesses. Furthermore, ORY-3001, an LSD1 inhibitor, is progressing through preclinical development with the aim of addressing non-cancerous dis...[Read more]

Industry

Biotechnology

IPO Date

2020-12-15

Stock Exchange

OTC

Ticker

ORYZF

The Current Ratio as of June 2026 (TTM) for Oryzon Genomics S.A. (ORYZF) is 1.83

According to Oryzon Genomics S.A.’s latest financial reports and current stock price. The company's current Current Ratio is 1.83. This represents a change of -14.01% compared to the average of 2.13 of the last 4 quarters.

Oryzon Genomics S.A. (ORYZF) Historical Current Ratio (quarterly & annually)

How has ORYZF Current Ratio performed in the past?

The mean historical Current Ratio of Oryzon Genomics S.A. over the last ten years is 50.09. The current 1.83 Current Ratio has changed 266.07% with respect to the historical average. Over the past ten years (40 quarters), ORYZF's Current Ratio was at its highest in in the June 2021 quarter at 6.39. The Current Ratio was at its lowest in in the March 2025 quarter at 0.44.

Quarterly (TTM)
Annual

Average

50.09

Median

3.58

Minimum

0.75

Maximum

475.40

Oryzon Genomics S.A. (ORYZF) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Oryzon Genomics S.A. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 13.82%

Maximum Annual Current Ratio = 475.40

Minimum Annual Increase = -98.84%

Minimum Annual Current Ratio = 0.75

Quarterly (TTM)
Annual
YearCurrent RatioChange
20251.95161.02%
20240.75-14.32%
20230.87-35.26%
20221.34-64.27%
20213.76-31.74%
20205.51-98.84%
2019475.4013.82%
20183.42-17.79%
20174.1510.84%
20163.75-12.46%

Oryzon Genomics S.A. (ORYZF) Average Current Ratio

How has ORYZF Current Ratio performed in the past?

The current Current Ratio of Oryzon Genomics S.A. (ORYZF) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

3-year avg

1.19

5-year avg

1.73

10-year avg

50.09

Oryzon Genomics S.A. (ORYZF) Current Ratio vs. Peers

How is ORYZF’s Current Ratio compared to its peers?

Oryzon Genomics S.A.’s Current Ratio is greater than hVIVO plc (1.63), less than Silence Therapeutics plc (9.83), greater than Santhera Pharmaceuticals Holding AG (1.29), less than Genfit S.A. (2.00), less than Transgene S.A. (9.62), less than Hansa Biopharma AB (publ) (3.63), greater than JW (Cayman) Therapeutics Co. Ltd (1.45), greater than NervGen Pharma Corp. (1.16), greater than China Evergrande New Energy Vehicle Group Limited (0.34), greater than Orpea S.A. (0.59),

Build a custom stock screener for Oryzon Genomics S.A. (ORYZF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oryzon Genomics S.A. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Oryzon Genomics S.A. (ORYZF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Oryzon Genomics S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Current Ratio?

How can you use the Current Ratio?

What is Oryzon Genomics S.A.'s Current Ratio?

How is the Current Ratio calculated for Oryzon Genomics S.A. (ORYZF)?

What is the highest Current Ratio for Oryzon Genomics S.A. (ORYZF)?

What is the 3-year average Current Ratio for Oryzon Genomics S.A. (ORYZF)?

What is the 5-year average Current Ratio for Oryzon Genomics S.A. (ORYZF)?

How does the current Current Ratio for Oryzon Genomics S.A. (ORYZF) compare to its historical average?